US Pre-Market SEC Filings Roundup β March 17, 2026
Overnight SEC filings from March 16-17, 2026 reveal mixed financial performance across sectors, with standout YoY revenue growth in select names like Mechanics Bancorp (+817% net income post-merger), Ethos Technologies (+52% revenue), and PURE Bioscience (+21.7% six-month revenue), contrasted by margin compressions in Dragonfly Energy (-250 bps gross margin QoQ) and Xerox Holdings (-440 bps total gross margin). SPAC and M&A activity dominates with positive sentiment around AParadise/Enhanced Games merger ($1.3B valuation), Pelican/Greenland energy deSPAC, and Two Harbors/UWM acquisition push, while activist pressure mounts at Lululemon via Dennis Wilson's 8.4% stake and board criticism. Capital allocation trends favor buybacks (First Industrial $250M program) and debt settlements (Integrated Rail), but dilutive financings (American Rebel 15% effective note, Hammer related-party loans) raise dilution risks. Forward-looking catalysts include BioCardia FDA pre-submission acceptance, Dragonfly Q1 2026 guidance ($9.5M sales, -$4.6M Adj EBITDA), and multiple proxy meetings (Carlisle April 29). Routine ABS servicing compliance in 10+ 10-Ks signals stable RMBS/ABS operations with no material issues. Portfolio-level, 7/15 high-materiality filers show revenue growth averaging +25% YoY but mixed profitability, favoring opportunistic plays in SPACs and post-merger banks amid pre-market positioning.